Pfizer's, Orbitz's Earnings, Jim Cramer is Charged Up for Today's Pick

We're awaiting earnings from Pfizer this morning, which is simultaneously trying to acquire U.K. drugmaker AstraZeneca--in a deal that may cost it much more than the $106 billion it already offered. Orbitz is set to report earnings as well--after underperforming competitors Priceline and Tripadvisor, analysts are forecasting a loss. And Jim Cramer is charged up over one pick he's saying could catch fire in emerging markets.